Cargando…
Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects. Gene therapy could provide sustained anti-VEGF levels after a si...
Autores principales: | She, Kaiqin, Su, Jing, Wang, Qingnan, Liu, Yi, Zhong, Xiaomei, Jin, Xiu, Zhao, Qinyu, Xiao, Jianlu, Li, Ruiting, Deng, Hongxin, Lu, Fang, Yang, Yang, Wei, Yuquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800040/ https://www.ncbi.nlm.nih.gov/pubmed/35141350 http://dx.doi.org/10.1016/j.omtm.2022.01.002 |
Ejemplares similares
-
Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration
por: She, Kaiqin, et al.
Publicado: (2023) -
Liver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler
por: Jin, Xiu, et al.
Publicado: (2022) -
In vivo adenine base editing corrects newborn murine model of Hurler syndrome
por: Su, Jing, et al.
Publicado: (2023) -
In vivo base editing rescues photoreceptors in a mouse model of retinitis pigmentosa
por: Su, Jing, et al.
Publicado: (2023) -
In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system
por: Li, Qian, et al.
Publicado: (2021)